Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programs

Read full text
Authors: Gitte Zels, Karen Van Baelen, A. C. Chang, Anirudh Pabba, Maxim De Schepper, Marion Maetens, François Richard, Josephine Van Cauwenberge, Tatjana Geukens, Kristien Borremans, Amena Mahdami, Ha-Linh Nguyen
+25 more Sophia Leduc, Patrick Neven, Hans P. M. W. Wildiers, Vincent Vandecaveye, Raphaëla Carmen Dresen, Wouter Van Den Bogaert, Rohit Bhargava, Tanner L. Bartholow, Neil M. Carleton, Ye Cao, Jie Bin Liu, A. Wedn, Hunter Waltermire, M. E. Cody, Lori Miller, Margaret Quinn Rosenzweig, Julia Foldi, Marija Balić, Christoper Deible, Christine Hodgdon, Walker, Stephanie, Adrian V. Lee, S Oesterreich, Giuseppe Floris, Christine Desmedt
Cited by: 0

Abstract

While primary invasive lobular carcinoma (ILC) is well characterized, metastatic ILC remains understudied. Within the post-mortem tissue donation programs, UPTIDER (Belgium) and Hope for Others (USA), we first aimed to explore intra-patient heterogeneity of key prognostic and predictive markers (stromal tumor-infiltrating lymphocytes (sTIL), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and KI67). Secondly, we compared detection of the metastases by pathology on autopsy samples versus pre-mortem imaging. In total, 306 metastases from 12 patients were collected at autopsy (median: 27 per patient). Both primary tumors (n = 15) and metastases (n = 232) had low sTIL levels, with a median of 2% (range: 0.67–6.67%) and 0.67% (range: 0–13.33%), respectively. Regression models showed lower ER- and PR-expression in metastases (respectively, n = 265 and n = 64) compared to primary tumors (both p < 0.01). KI67 was significantly higher in metastases (n = 262, p = 0.02). HER2-low metastases were found in all but one patient although in varying proportion of metastases (range: 7.5–100%). Central radiology and pathology review had a median concordance of 78% at organ level (range: 33.33–100%) and 71% (range: 55.88–85.29%) at patient level. Our findings suggest that a single metastatic biopsy has great limitations to guide treatment and that more adequate methods are needed to detect and monitor ILC metastases.

Fields of Study & Subjects

Breast Lesions and Carcinomas Breast Cancer Treatment Studies Metastasis and carcinoma case studies

Publication details

Journal / source
Code Ocean
Publication date
1 January 2026
Language
EN